FR12C0064I1 - - Google Patents

Info

Publication number
FR12C0064I1
FR12C0064I1 FR12C0064C FR12C0064I1 FR 12C0064 I1 FR12C0064 I1 FR 12C0064I1 FR 12C0064 C FR12C0064 C FR 12C0064C FR 12C0064 I1 FR12C0064 I1 FR 12C0064I1
Authority
FR
France
Prior art keywords
isoquinoline
aminoethyl
benzo
dextran
lactose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR12C0064I1 publication Critical patent/FR12C0064I1/fr
Application granted granted Critical
Publication of FR12C0064I2 publication Critical patent/FR12C0064I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Injectable pharmaceutical compositions containing 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimaleate as active ingredient in the form of a lyophilised powder with a carrier selected from lactose and dextran, mixed with sodium chloride.
FR12C0064C 2002-05-16 2012-10-25 INJECTABLE PHARMACEUTICAL COMPOSITIONS OF AN ANTHRACENEDIONE DERIVATIVE WITH ANTITUMOR ACTION Active FR12C0064I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002MI001040A ITMI20021040A1 (en) 2002-05-16 2002-05-16 INJECTABLE PHARMACEUTICAL COMPOSITIONS OF AN ANTHROCENEDIONAL DERIVATIVE WITH ANTI-TUMOR ACTIVITY
PCT/EP2003/004871 WO2003097101A1 (en) 2002-05-16 2003-05-09 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity

Publications (2)

Publication Number Publication Date
FR12C0064I1 true FR12C0064I1 (en) 2012-12-14
FR12C0064I2 FR12C0064I2 (en) 2013-08-16

Family

ID=11449903

Family Applications (1)

Application Number Title Priority Date Filing Date
FR12C0064C Active FR12C0064I2 (en) 2002-05-16 2012-10-25 INJECTABLE PHARMACEUTICAL COMPOSITIONS OF AN ANTHRACENEDIONE DERIVATIVE WITH ANTITUMOR ACTION

Country Status (12)

Country Link
US (3) US20060199831A1 (en)
EP (1) EP1503797B1 (en)
JP (1) JP4624780B2 (en)
AT (1) ATE381944T1 (en)
AU (1) AU2003240613A1 (en)
CA (1) CA2486001C (en)
DE (1) DE60318310T2 (en)
ES (1) ES2298521T3 (en)
FR (1) FR12C0064I2 (en)
IT (1) ITMI20021040A1 (en)
MX (1) MXPA04011348A (en)
WO (1) WO2003097101A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
CN108186560A (en) * 2016-03-26 2018-06-22 夏建明 A kind of parenteral solution for treating non-Hodgkin lymphoma and preparation method thereof
CN108113967A (en) * 2016-03-26 2018-06-05 夏建明 A kind of freeze-dried composition for treating non-Hodgkin lymphoma and preparation method thereof
CN105997896B (en) * 2016-05-28 2019-07-05 长沙秋点兵信息科技有限公司 The injection freeze-dried powder and preparation method thereof for treating non-Hodgkin lymphoma
CN106176630B (en) * 2016-08-03 2019-01-04 湖北丽益医药科技有限公司 A kind of preparation method of injection maleic acid Pixantrone aseptic powdery

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3590124A (en) * 1967-06-27 1971-06-29 Us Navy Blood transfusion fluids having reduced turbulent friction properties
JP2690009B2 (en) * 1986-07-10 1997-12-10 エーザイ 株式会社 Cefalosporin injection
NZ241868A (en) 1991-03-08 1995-05-26 Univ Vermont 6,9-bis(substituted-amino)benzo[g]isoquinoline-5,10-diones, preparation and pharmaceutical compositions thereof
JP3501471B2 (en) * 1992-06-15 2004-03-02 旭化成ファーマ株式会社 Stabilizing composition and method of calcitonin
JPH08126685A (en) * 1994-01-26 1996-05-21 Shionogi & Co Ltd Lyophilization of dextran compound
US5587382A (en) * 1994-03-28 1996-12-24 Boehringer Mannheim Italia, Spa 6,9-bis[(2-aminoethyl) amino]benzo [g]isoquinoline-5,10- dione dimaleate; an aza-anthracenedione with reduced cardiotoxicity
MY122499A (en) * 1997-11-10 2006-04-29 Searle & Co Use of alkylated iminosugars to treat multidrug resistance
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
IT1315253B1 (en) * 1999-10-22 2003-02-03 Novuspharma Spa LIPOSOMIAL PREPARATION OF 6,9-BIS- (2-AMINOXYL) AMINO | BENZOG | ISOCHINOLIN-5,10-DIONE DIMALEATO

Also Published As

Publication number Publication date
JP4624780B2 (en) 2011-02-02
US20110144147A1 (en) 2011-06-16
JP2005530792A (en) 2005-10-13
ATE381944T1 (en) 2008-01-15
CA2486001A1 (en) 2003-11-27
AU2003240613A1 (en) 2003-12-02
EP1503797A1 (en) 2005-02-09
DE60318310T2 (en) 2008-12-11
DE60318310D1 (en) 2008-02-07
EP1503797B1 (en) 2007-12-26
ITMI20021040A1 (en) 2003-11-17
ES2298521T3 (en) 2008-05-16
US9211262B2 (en) 2015-12-15
FR12C0064I2 (en) 2013-08-16
ITMI20021040A0 (en) 2002-05-16
US20160256557A1 (en) 2016-09-08
MXPA04011348A (en) 2005-08-15
US20060199831A1 (en) 2006-09-07
WO2003097101A1 (en) 2003-11-27
CA2486001C (en) 2010-04-13

Similar Documents

Publication Publication Date Title
HK1036970A1 (en) Compounds and compositions for delivering active agents.
FR12C0064I1 (en)
GEP20074099B (en) 3-β-D-RIBOFURANO-SYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
MY125516A (en) Novel composition based on thiazolidinedione and metformin and use
MY125921A (en) Compositions containing organic compounds
EP1015008A4 (en) Compounds and compositions for delivering active agents
AU1453200A (en) Cyclic peptide ligands that target urokinase plasminogen activator receptor, their pharmaceutical compositions and use
HK1036969A1 (en) Compounds and compositions for delivering active agents
MXPA01008611A (en) Compounds and compositions for delivering active agents.
HK1065483A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
IL153297A0 (en) Compounds and compositions for delivering active agents
IL188774A0 (en) Compositions for delivery of drug combinations
PL350456A1 (en) N−cyanomethylamides as protease inhibitors
PT1083884E (en) PROCESS FOR THE STABILIZATION OF POLYVINYL-PYRROLIDONE COMPOSITIONS
AU2274201A (en) Compounds and compositions for delivering active agents
IL162141A0 (en) Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemoterapy
HK1029124A1 (en) Lh-rh peptide analogues, their uses and pharmaceutical compositions containing them.
HK1024177A1 (en) Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles
NZ511085A (en) Oral pharmaceutical compositions containing buprenorphin
YU13301A (en) Muscarinic agonists and antagonists
GEP20063972B (en) Streptogramin derivatives, preparation and compositions containing them
ES2189456T3 (en) INJECTABLE WATERPROOF COMPOSITION.
DK1268522T3 (en) LH-RH antagonists as well as their preparation and use thereof as drugs
BG106151A (en) Pharmaceutical complex
MXPA02012015A (en) Ligands of integrin receptors.